HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges

By Lordick Florian  

Clinical and Translational Oncology, Vol. 13, Iss. 9, 2011-09 ,pp. : 597-598

Springer Publishing Company

Access to resources Recommend Favorite

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

By Rugo Hope   Brufsky Adam   Yood Marianne   Tripathy Debu   Kaufman Peter   Mayer Musa   Yoo Bongin   Abidoye Oyewale   Yardley Denise  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 461-470

Springer Publishing Company

Access to resources Recommend Favorite

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

By                  

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1204-1212

Spandidos Publications

Access to resources Recommend Favorite

Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer

By Modi Shanu   DiGiovanna Michael   Lu Zhao   Moskowitz Chaya   Panageas Katherine   Van Poznak Catherine   Hudis Clifford   Norton Larry   Tan Lee   Stern David   Carter Darryl   Seidman Andrew  

Cancer Investigation, Vol. 23, Iss. 6, 2005-09 ,pp. : 483-487

Informa Healthcare

Access to resources Recommend Favorite

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer

By  

Cancer Medicine, Vol. 4, Iss. 9, 2015-09 ,pp. : 1344-1355

John Wiley & Sons Inc

Access to resources Recommend Favorite